Press Release FeedGet the RSS feed
Menu

Business Wire

Poxel Reports Revenue for the Third Quarter of 2026

Business Wire

  • Consolidated net sales of TWYMEEG® in Japan for the third quarter of 2026 reached JPY 2.9 billion (€16.3 million1), up 29% compared to the third quarter of 2025.

  • Consolidated net sales of TWYMEEG® in Japan for the first nine months of 2026 reached JPY 8.1 billion (€44.5 million1), up 32% compared to the first nine months of 2025.

  • Net sales of TWYMEEG® exceeded the contractual threshold of JPY 5 billion in the first half of Sumitomo Pharma's fiscal year 20262: Poxel's royalty rate increases from 8% to 10% on all net sales for the fiscal year, effective retroactively.

  • Poxel thus generates positive net royalties for the first time (including royalties owed to Merck Serono) during Sumitomo Pharma's fiscal year 2026.

  • Poxel reported revenue of €1,951k in the third quarter of 2026, including a €322k retroactive adjustment to royalties from the second quarter of 2026.

  • Sumitomo Pharma expects net sales of TWYMEEG® to exceed JPY 10 billion in its fiscal year 20263.

  • Upon reaching this milestone, Poxel will receive a contractual bonus of JPY 1 billion (€5.6 million¹); the royalty rate will increase from 10% to 12%.

LYON, France, October 19, 2026--Regulatory News:

POXEL SA (Paris:POXEL) (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company that has developed innovative treatments for serious chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases, today announces its revenue for the third quarter ended September 30, 2026, and for the first nine months of the fiscal year.

Commercial Activity Update

TWYMEEG® (Imeglimin)

  • For the quarter ended September 2026, TWYMEEG® net sales in Japan increased by 29% to JPY 2.9 billion (€16.3 million¹) compared to sales of JPY 2.3 billion for the quarter ended September 2025, as reported by Sumitomo Pharma. Gross sales for the quarter totaled JPY 3.3 billion, up 29%.

  • In the first half of its 2026 fiscal year (April–September 2026), Sumitomo Pharma's net sales of TWYMEEG® reached JPY 5.8 billion, up 30% from the first half of the previous fiscal year. Sumitomo Pharma expects that net sales of TWYMEEG® could exceed JPY 10 billion for the fiscal year, entitling Poxel to receive royalties of 12% on all net sales of TWYMEEG® and a payment of JPY 1 billion (€5.6 million¹). In accordance with the royalty monetization agreement entered with OrbiMed, the proceeds will be used exclusively to repay the bond issue.

Consolidated Revenue for the Third Quarter and the First Nine Months of 2026

  1. HealthcarePureTech Announces Presentation of Phase 1b Results for LYT-200 in Relapsed/Refractory (R/R) High-Risk Myelodysplastic Syndromes (HR-MDS) and Acute Myeloid Leukemia (AML) at ESMO 2026Oral presentation to highlight encouraging clinical activity and favorable safety of LYT-200 in heavily pretreated patients with R/R HR-MDS and AML Results reinforce the potential of LYT-200 as a first-in-class, mutation-agnostic treatment for a broad R/R HR-MDS population, where treatment options remain extremely limited
  2. SaaSeLstar Dynamics Launches the World’s First Commercial ELM Smart Glass Solution for Architectural Glazing, Harking in a New Era for Controlling Sunlight Without Compromising DesignExplore eLstar's Latest Smart Glass Innovations at Glasstec in Düsseldorf in Hall 10, Stand A12 DUSSELDORF, Germany, October 19, 2026--Today at Glasstec 2026, eLstar Dynamics announced the commercial availability of its first Electrophoretic Light Modulation (ELM) Platform . Purpose-built specifically
  3. Azelis: Transparency notifications from UBS Group AGCompanies: UBSANTWERP, Belgium, October 19, 2026--REGULATED INFORMATION In accordance with Article 14 of the Belgian Transparency law of 2 May 2007, Azelis Group NV (Brussels:AZE) announces that on 13 October 2026, it has received two transparency notifications from UBS Group AG. 1. Summary of the notifications UBS
  4. FinanceBW LPG LimitedBW LPG Limited – Update on BW LPG’s Product Services Q3 2026 Segment PerformanceSINGAPORE, October 19, 2026--BW LPG Limited ("BW LPG" or the "Company", OSE ticker code: "BWLPG.OL", NYSE ticker code: "BWLP") today provides an update on its Product Services' ("BW Product Services") Q3 2026 segment performance. Q3 2026 highlights: Gross trading result: US$164 million This includes: R
  5. HealthcareGenentechGenentech to Present Pivotal Data at ESMO 2026, Showcasing Advances Across Its Lung and Breast Cancer Late-Stage PortfolioPhase III Krascendo 1 results demonstrated divarasib's superiority over current standard of care, first-generation KRAS G12C inhibitors, in previously treated advanced G12C-mutated non-small cell lung cancer Patient-reported outcomes from Phase III lidERA study showed improved efficacy of giredestrant over standard endocr
  6. FinanceMon courtier énergie group: Net Income Up 80% in the First Half of 2026, Driven by Growth and Improved ProfitabilityHalf-year revenue of €16.5 million, up 14% Operating income of €2.2 million, up 49%, representing a margin of 13% Net income attributable to the Group of €1.8 million, up 80% Contract renewals representing 60% of revenue, compared with 50% a year earlier 2026 financial targets confirmed BORDEAUX, France, October 19, 2026